Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted a significant decline in revenue and gross margin, alongside a net loss, indicating financial struggles. Although operating expenses decreased due to asset divestitures, the overall financial health is concerning. The Q&A session revealed potential growth opportunities, but also increased expenses due to a new sales force. Despite some optimism in product expansion, the weak financial performance and increased debt pose risks, leading to a negative sentiment.
Key Financial Performance
Total Revenue (Q1 2026) $20.9 million, compared to $32.9 million in Q1 2025 on a pro forma basis. The decline was primarily due to headwinds related to amnio product revenue tied to the advanced wound care market.
Gross Margin (Q1 2026) 57.3%, compared to 61.5% in Q1 2025. The decrease was due to the cessation of Q-code license revenue from amniotic membrane agreements that ended in 2025, partly offset by improvements in product mix.
Operating Expenses (Q1 2026) $14.9 million, compared to $19.2 million in Q1 2025. The decrease was primarily due to the sale of noncore Coflex and CoFix assets and international hardware business to Companion Spine in December 2025.
General and Administrative Expenses (Q1 2026) $6.3 million, compared to $7.5 million in Q1 2025. The decrease was due to the divestiture of assets and businesses to Companion Spine in December 2025.
Sales and Marketing Expenses (Q1 2026) $8.2 million, compared to $11.2 million in Q1 2025. The decrease was due to the Companion Spine divestitures ($2.5 million reduction), lower independent agent commissions ($0.4 million reduction), and a $0.6 million decrease in professional fees.
Research and Development Expenses (Q1 2026) $435,000, essentially flat compared to $443,000 in Q1 2025.
Net Loss (Q1 2026) $3.1 million or $0.02 per share, compared to net income of $58,000 in Q1 2025. The change was due to reduced revenue and other financial adjustments.
Adjusted EBITDA (Q1 2026) Loss of $1.6 million, compared to positive adjusted EBITDA of $3 million in Q1 2025. The decline was due to reduced revenue and financial adjustments.
Cash and Cash Equivalents (March 31, 2026) $12.2 million, compared to $17.3 million as of December 31, 2025. The reduction was due to repayments of debt using proceeds from the Companion Spine transaction.
Total Indebtedness (March 31, 2026) $12.2 million, compared to $25.4 million as of December 31, 2025. The reduction was due to a $2.8 million term-loan payment and $10.4 million in net repayments on the revolving credit facility.
Availability Under Revolving Credit Facility (March 31, 2026) $11.8 million, compared to $3.8 million as of December 31, 2025. The increase was due to efforts to reduce interest expense by minimizing the outstanding balance on the revolving credit facility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Commercial launch of Trivium Shaped: An extension of the Trivium bone graft portfolio, offering pre-shaped configurations for enhanced surgical handling and preparation. This innovation builds on the Trivium sculptable format launched in April 2025.
HEMOBLAST Bellows product: Acquired exclusive U.S. distribution rights to this hemostatic agent, entering a $2 billion global market. It is highly differentiated and requires no preparation prior to use.
Entry into the hemostatic agent market: Secured a transformational license agreement with Dilon Technologies, providing access to a $2 billion global market.
Strengthened balance sheet: Reduced total indebtedness by $13.3 million in Q1 2026, including reductions in revolving credit and term loan balances.
Expansion of sales team: Hired 21 sales professionals from Dilon Technologies and doubled the number of regional sales reps in 2026.
Focus on high-margin biologics business: Divested non-core Coflex assets and Paradigm businesses for $21.4 million, allowing focus on core biologics.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company experienced a decline in revenue for Q1 2026 compared to Q1 2025 on a pro forma basis, primarily due to headwinds in the amnio product revenue tied to the advanced wound care market.
Gross Margin Decrease: Gross margin decreased from 61.5% in Q1 2025 to 57.3% in Q1 2026, driven by the cessation of Q-code license revenue from amniotic membrane agreements due to changes in the reimbursement environment.
Net Loss: The company reported a net loss of $3.1 million in Q1 2026 compared to net income of $58,000 in Q1 2025, indicating financial challenges.
Adjusted EBITDA Loss: Adjusted EBITDA for Q1 2026 was a loss of $1.6 million compared to positive adjusted EBITDA of $3 million in Q1 2025, reflecting operational inefficiencies or increased costs.
Reimbursement Environment Changes: Changes in the reimbursement environment led to the termination of amniotic membrane agreements, negatively impacting revenue and gross margin.
Debt Levels: Although the company reduced its total indebtedness, it still carries $12.2 million in debt, which could pose financial risks if revenue growth does not materialize as expected.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Revenue Guidance: The company has raised its full-year 2026 revenue guidance to a range of $101 million to $105 million, reflecting the addition of the HEMOBLAST Bellows product and growth in the base business.
Market Entry and Growth Potential: The company has entered the $2 billion global addressable market for hemostatic products through the exclusive U.S. distribution rights to Dilon's HEMOBLAST Bellows product. This product is expected to enhance the biologics portfolio and drive institutional adoption.
Sales Force Expansion: The company plans to double the number of regional sales representatives in 2026 and add significant resources to the national accounts team to expand institutional adoption and scale across hospital systems and large practice groups.
Product Portfolio Expansion: The commercial launch of Trivium Shaped, an extension of the Trivium bone graft portfolio, is expected to optimize surgical workflows and enhance clinical utility, contributing to future growth.
Strategic Focus on Biologics: The company is focusing on its core high-margin biologics business, which is expected to drive future growth and competitive differentiation.
Revenue Growth Drivers: Accelerating biologics growth is anticipated for the remainder of 2026 and beyond, driven by the Dilon Technologies license agreement, new product introductions, and investments in the sales force.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an overview of the relationships and capabilities of the new sales force for HEMOBLAST, and discuss its use cases and growth opportunities?
A:The HEMOBLAST business is currently small and focused on general surgery. The new sales force will help expand into the spine market, the largest segment in the hemostatic market. Additionally, they will explore opportunities in urology and other hospital call points where collagen and amnio products can be used. This expansion opens up significant growth opportunities.
Q:Will the new sales force have access to the entire product portfolio, and how will this impact expenses?
A:Initially, the sales force will focus on HEMOBLAST and complementary products like collagen and amnio lines. Over time, they will gain access to the full product portfolio. The addition of 21 seasoned sales reps will increase sales and marketing expenses by approximately $2.5 million quarterly, including $1.5 million annually for travel and marketing.
Q:What is the current status and growth outlook for the ortho-biologics segment?
A:Growth is driven by new products like OsteoFactor Pro and Trivium product lines. While stem-cell products showed some softness in Q1 due to OEM-related lumpiness, advanced biologics sales, including collagen and amnio products, are expected to pick up in the second half of the year. The advanced wound care segment also shows potential for improvement.
Q:What is the expected gross margin cadence for the remainder of the year?
A:Gross margins are expected to remain in the low 60s for the rest of the year. Q1 saw a slight deviation due to excess and obsolete expenses and product mix, but margins are expected to stabilize in Q3 and Q4.
Q:What feedback have you received regarding HEMOBLAST, and what is the growth potential for Trivium Shaped?
A:HEMOBLAST is a high-performing product with broad use cases, but it is not well-known due to competition from larger companies. The new sales force is expected to significantly increase its reach and adoption. Trivium Shaped offers an advanced solution compared to existing products like OsteoSelect and 3Demin, with better performance and significant growth potential.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses provided sufficient detail and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bellows product
Coflex
Dilon Technologies
HEMOBLAST Bellows
Trivium Shaped
Xtant Medical
addition HEMOBLAST
agreement Dilon
allograft
amnio
balance sheet
bone matrix
collagen
configuration
differentiation
distribution
divestiture
graft
hospital system
launch Trivium
line
market
milestone
need
partner
portfolio
practice
preparation
sale
surgeon
transaction
update
use
XTNT Transcript
Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call highlighted a significant decline in revenue and gross margin, alongside a net loss, indicating financial struggles. Although operating expenses decreased due to asset divestitures, the overall financial health is concerning. The Q&A session revealed potential growth opportunities, but also increased expenses due to a new sales force. Despite some optimism in product expansion, the weak financial performance and increased debt pose risks, leading to a negative sentiment.
Xtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call Transcript
Positive3-31
The earnings call reveals strong financial performance with a 12% revenue increase, improved gross margins, and a turnaround to net income. Despite a 5% rise in operating expenses, cash flow from operations increased significantly. The absence of strategic or operational updates limits the upside, but the financial metrics alone suggest a positive sentiment. No critical concerns were raised in the Q&A. Given these factors, a positive stock price movement of 2% to 8% is expected over the next two weeks.
Xtant Medical Holdings, Inc. (XTNT) Q3 2025 Earnings Call Transcript
Positive11-11
The company reported strong financial results, including a 19% revenue increase and a shift from a net loss to a net income, coupled with improved gross margins and reduced operating expenses. The raised revenue guidance and strategic moves like asset sales and increased sales force indicate optimism. Despite some concerns about inventory and reliance on cost-cutting, the positive guidance and strategic focus on profitability and cash generation suggest a positive stock reaction.
Xtant Medical Holdings, Inc. (XTNT) Q2 2025 Earnings Call Transcript
Positive8-12
Xtant Medical's earnings call presents a positive outlook with a strong financial performance, including an 18% revenue increase and improved gross margins. The strategic focus on biologics and vertical integration, along with cost-cutting measures, enhances profitability. Despite some uncertainties in licensing revenue and regulatory risks, the optimistic 2025 guidance, new product launches, and improved cash flow from asset sales contribute to a positive sentiment. The Q&A reveals cautious optimism, with management addressing concerns about future licensing revenue. Overall, the company's strategic moves and financial performance suggest a positive stock price movement.
XTNT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
